Clinical Trial Update: A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of bortezomib in relapsed or refractory multiple myeloma completed in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Refractory, Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED